Net Reclassification Indices for Evaluating Risk Prediction Instruments
2013 · Epidemiology · 405 citations
https://doi.org/10.1097/ede.0000000000000018
H
Holly Janes
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
218
Papers
12.6K
Citations
44
h-index
106
i10-index
Holly Janes is an academic researcher from Fred Hutch Cancer Center. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & HIV Research and Treatment & Statistical Methods in Clinical Trials. The author has an h-index of 44, co-authored 186 publications.
ORCID: 0000-0002-3237-984XPapers by this author
worksSafety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
2019 · The Lancet HIV · 50 citations
https://doi.org/10.1016/s2352-3018(19)30262-0
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
2022 · BMC Infectious Diseases · 26 citations
https://doi.org/10.1186/s12879-022-07639-1
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial
2016 · Current Opinion in Virology · 14 citations
https://doi.org/10.1016/j.coviro.2016.01.007
Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
2020 · Scientific Reports · 10 citations
https://doi.org/10.1038/s41598-020-69007-w
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
2024 · Nature Communications · 7 citations
https://doi.org/10.1038/s41467-024-52348-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat